News | May 29, 2024
IGC Pharma announces patient enrollment at Neurostudies in Phase 2 trial investigating IGC-AD1
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Breakthrough Therapy designation for pain associated with DPN granted by FDA
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
US FDA approval based on NEURO-TTRansform Phase III results
KBR will provide outreach, education and data analytics to support critical neuroscience research for the prevention and treatment of military members with CTE
The cognitively operated system is a mother patent invention, first launched in India
Mindset disagrees with and denies the allegations set forth from Reunion.
Subscribe To Our Newsletter & Stay Updated
